Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess safety of eltrombopag in pediatric patients undergoing intensive
chemotherapy for malignant solid tumors.
Secondary Objectives: To assess the efficacy of eltrombopag in increasing platelet count up
to 2 weeks after completion of chemotherapy in pediatric patients undergoing intensive
chemotherapy for malignant solid tumors.
Hypothesis: The hypothesis is that eltrombopag an oral thrombopoietin receptor agonist will
increase the platelet count safely and efficaciously in children having chemotherapy induced
thrombocytopenia while on therapy for solid tumors.